Listen to Mark Rubin on the next prostate cancer Cure Panel Talk Show

The next prostate cancer Cure Panel Talk Show will be hosting Mark Rubin, MD of Weill Cornell Medical College on May 31 at 4:00 pm EST. The show will be co-hosted by Dan Zenka  of the Prostate Cancer Foundation. … READ MORE …

“Raising the bar” for outcomes after radical prostatectomy

There is another rather entertaining, 10-minute video today on the Medscape Oncology web site showing a conversation  between Dr. Matt Cooperberg of the University of California, San Francisco and Dr. Andrew Vickers of the Memorial Sloan-Kettering Cancer Center in New York. … READ MORE …

Baseline data from the control arm of the STAMPEDE trial

One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. … READ MORE …

Vasectomy and risk for prostate cancer all over again

Over the years there has been controversy as to the existence of an association between vasectomy and risk for prostate cancer. A new set of data from a large, long-term study, to be presented at the upcoming annual meeting of the American Society of Clinical Oncology, has shown that there is, indeed, such a risk — but it is specific to high-risk prostate cancer. … READ MORE …

Life expectancy ≤ 10 years and the risks associated with treatment

According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, “Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they’d have to live with their side effects.” … READ MORE …

Prostate Cancer Roundtable comments on plethora of guidelines on screening

As many readers will be aware, there have been two new sets of guidance about screening for prostate cancer issued in the past few months — the most recent from the American Urological Association just a couple of weeks ago. … READ MORE …

Expert opinion on ADT for CRPC today

As regular readers will be well aware, the implementation of varying types of androgen deprivation therapy (ADT) in hormone-sensitive and in castration-resistant forms of progressive prostate cancer is evolving. Five or so years from now we may be looking at a very different set of ways to use ADT than those we have been used to. … READ MORE …

Can we really re-frame low-risk prostate cancer as a chronic disease?

Many readers of this web site may be interested in a video discussion on the Medscape web site between two relatively young urologists about the implications of the Prostate Outcomes Outcomes Study (PCOS), on which we commented a few months back. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 832 other followers